CStone Pharmaceuticals (HKG:2616) plans to issue up to 80 million shares to at least six investors under a placement deal at HK$2.933 apiece, according to a Wednesday filing with the Hong Kong bourse.
The shares comprise 5.86% of the entire share capital of the drug company following completion.
Net proceeds, estimated at HK$232.3 million, will be used for the development of cancer drugs and for other general corporate purposes.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。
沒有相關數據
如果下載按鈕點擊無跳轉,請點擊右上角菜單選擇 “在瀏覽器打開”